In adenocarcinomas, common alterations included ASXL2 and TP53. In carcinomas NOS, frequent mutations included FGF23, FGF6, GEN1, KRAS, MST1, PTPRD, and TP53 (Fig. 2c; Data S1B). Here, PTPRD is linked to carcinoma.